Literature DB >> 17627716

Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs.

P Lindgren1, F Borgström, J Stålhammar, E Alemao, L Jönsson.   

Abstract

BACKGROUND: Less than half of patients in Scandinavian societies achieve target cholesterol values established by consensus coronary prevention panels. METHODS AND
RESULTS: Using logistic regression analysis, we determined that patients not at consensus cholesterol goals after 3 months of treatment using lipid-lowering medications were significantly more likely to achieve these goals at 12 months if they were treated with an active management strategy (changes in lipid-lowering therapy within 3 months), had a diagnosis of diabetes mellitus, or initiated lipid-lowering more recently, compared with their counterparts without these factors.
CONCLUSION: An active management strategy is associated with a higher probability of achieving treatment goals in patients not at goal after 3 months following treatment initiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627716     DOI: 10.1111/j.1742-1241.2007.01468.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  3 in total

1.  Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy.

Authors:  John T Lynch; Catherine E Cooke; Jonathan Rosen; Sanjay Gandhi; Michael F Bullano
Journal:  Am Health Drug Benefits       Date:  2010-09

2.  Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).

Authors:  Billie Pettersson; Baishali Ambegaonkar; Vasilisa Sazonov; Mats Martinell; Jan Stålhammar; Per Wändell
Journal:  BMC Public Health       Date:  2010-11-29       Impact factor: 3.295

3.  Automated data extraction--a feasible way to construct patient registers of primary care utilization.

Authors:  Mats Martinell; Jan Stålhammar; Johan Hallqvist
Journal:  Ups J Med Sci       Date:  2012-03       Impact factor: 2.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.